CDK1-mediated SIRT3 activation enhances mitochondrial function and tumor radioresistance

Molecular Cancer Therapeutics

Volumn 14, Issue 9, 2015, Pages 2090-2102

  Liu, Rui ^a   Fan, Ming ^a   Candas, Demet ^a   Qin, Lili ^a   Zhang, Xiaodi ^a   Eldridge, Angela ^a   Zou, June X ^a   Zhang, Tieqiao ^a   Juma, Shuaib ^a   Jin, Cuihong ^a   Li, Robert F ^a   Perks, Julian ^a,b   Sun, Lun Quan ^c   Vaughan, Andrew T M ^a,b   Hai, Chun Xu ^d   Gius, David R ^e   Li, Jian Jian ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL PROTEIN; SERINE; SIRTUIN 3; THREONINE; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CLONOGENESIS; CONTROLLED STUDY; DEACETYLATION; ENZYME ACTIVITY; GLIOBLASTOMA CELL LINE; HCT116 CELL LINE; HUMAN; HUMAN CELL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RADIOSENSITIVITY; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; ACETYLATION; ANIMAL; DISEASE MODEL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MUTATION; NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

ACETYLATION; ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MUTATION; NEOPLASMS; NF-KAPPA B; PHOSPHORYLATION; RADIATION TOLERANCE; SIRTUIN 3; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84942082375     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0017     Document Type: Article

References (53)

1. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:1356-61.
2. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90.
3. Peters LJ, O'Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010;28:2996-3001.
4. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003;2:1113-20.
5. Debeb BG, Xu W, Woodward WA. Radiation resistance of breast cancer stem cells: understanding the clinical framework. J Mammary Gland Biol Neoplasia 2009;14:11-7.
6. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
7. Ahmed KM, Dong S, Fan M, Li JJ. Nuclear factor-kappaB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells. Mol Cancer Res 2006;4:945-55.
8. Guo G, Yan-Sanders Y, Lyn-Cook BD, Wang T, Tamae D, Ogi J, et al. Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. Mol Cell Biol 2003;23:2362-78.
9. Gupta S, Koru-Sengul T, Arnold SM, Devi GR, Mohiuddin M, Ahmed MM. Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells. Mol Cancer Ther 2011;10:292-302.
10. Hadian K, Krappmann D. Signals from the nucleus: activation of NF-kappaB by cytosolic ATM in the DNA damage response. Sci Signal 2011;4:pe2.
11. Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, Fan M, et al. NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res 2009;171:9-21.
12. Wang Z, Cao N, Nantajit D, Fan M, Liu Y, Li JJ. Mitogen-activated protein kinase phosphatase-1 represses c-Jun NH2-terminal kinase-mediated apoptosis via NF-kappaB regulation. J Biol Chem 2008;283:21011-23.
13. Huang JY, Hirschey MD, Shimazu T, Ho L, Verdin E. Mitochondrial sirtuins. Biochim Biophys Acta 2010;1804:1645-51.
14. He W, Newman JC, Wang MZ, Ho L, Verdin E. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab 2012;23:467-76.
15. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012;13:225-38.
16. Hallows WC, Albaugh BN, Denu JM. Where in the cell is SIRT3?-functional localization of an NAD+-dependent protein deacetylase. Biochem J 2008;411:e11-3.
17. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol 2008;382:790-801.
18. Shimazu T, Hirschey MD, Huang JY, Ho LT, Verdin E. Acetate metabolism and aging: an emerging connection. Mech Ageing Dev 2010;131:511-6.
19. Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, Someya S, et al. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell 2011;41:139-49.
20. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010;464:121-5.
21. Yu W, Dittenhafer-Reed KE, Denu JM. SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J Biol Chem 2012;287:14078-86.
22. Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 2010;35:669-75.
23. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009;460:587-91.
24. Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 2007;21:920-8.
25. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A 2008;105:14447-52.
26. Fernandez-Marcos PJ, Jeninga EH, Canto C, Harach T, de Boer VC, Andreux P, et al. Muscle or liver-specific Sirt3 deficiency induces hyperacetylation of mitochondrial proteins without affecting global metabolic homeostasis. Sci Rep 2012;2:425.
27. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, etal. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 2010;40:893-904.
28. Vassilopoulos A, Pennington DJ, Andresson T, Rees D, Fearnley I, Ham A, et al. SIRT3 deacetylates ATP synthase F1 complex proteins in response to nutrient and exercise-induced stress. Antioxid Redox Signal 2014;21:551-64.
29. Cheng Y, Ren X, Gowda AS, Shan Y, Zhang L, Yuan YS, et al. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress. Cell Death Dis 2013;4:e731.
30. Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ, et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011;117:1670-8.
31. 2/M progression. Dev Cell 2014;29:217-32.
32. Candas D, Fan M, Nantajit D, Vaughan AT, Murley JS, Woloschak GE, et al. CyclinB1/Cdk1 phosphorylates mitochondrial antioxidant MnSOD in cell adaptive response to radiation stress. J Mol Cell Biol 2013;5:166-75.
33. Takeda DY, Wohlschlegel JA, Dutta A. A bipartite substrate recognition motif for cyclin-dependent kinases. J Biol Chem 2001;276:1993-7.
34. Averbeck NB, Durante M. Protein acetylation within the cellular response to radiation. J Cell Physiol 2011;226:962-7.
35. Ahmed KM, Li JJ. NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 2008;44:1-13.
36. Bell EL, Guarente L. The SirT3 divining rod points to oxidative stress. Mol Cell 2011;42:561-8.
37. Brown K, Xie S, Qiu X, Mohrin M, Shin J, Liu Y, et al. SIRT3 reverses aging-associated degeneration. Cell Rep 2013;3:319-27.
38. Jacobs KM, Pennington JD, Bisht KS, Aykin-Burns N, Kim HS, Mishra M, et al. SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression. Int J Biol Sci 2008;4:291-9.
39. Satterstrom FK, Haigis MC. Luciferase-based reporter to monitor the transcriptional activity of the SIRT3 promoter. Methods Enzymol 2014;543:141-63.
40. Bradbury CM, Markovina S, Wei SJ, Rene LM, Zoberi I, Horikoshi N, et al. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res 2001;61:7689-96.
41. Delhalle S, Blasius R, Dicato M, Diederich M. A beginner's guide to NF-kappaB signaling pathways. Ann N Y Acad Sci 2004;1030:1-13.
42. Jung M, Dritschilo A. NF-kappa B signaling pathway as a target for human tumor radiosensitization. Semin Radiat Oncol 2001;11:346-51.
43. Weichselbaum RR, Hallahan D, Fuks Z, Kufe D. Radiation induction of immediate early genes: effectors of the radiation-stress response. Int J Radiat Oncol Biol Phys 1994;30:229-34.
44. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, et al. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 2000;60:1085-9.
45. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004;101:10137-42.
46. Helbig G, Christopherson KW II, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631-8.
47. Candas D, Lu CL, Fan M, Chuang FY, Sweeney C, Borowsky AD, et al. Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells. Cancer Res 2014;74:7498-509.
48. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S, et al. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep 2011;12:534-41.
49. Oberley LW, Buettner GR. Role of superoxide dismutase in cancer: a review. Cancer Res 1979;39:1141-9.
50. Liu J, Gu X, Robbins D, Li G, Shi R, McCord JM, et al. Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model. PLoS ONE 2009;4:e5284.
51. Indo HP, Inanami O, Koumura T, Suenaga S, Yen HC, Kakinuma S, et al. Roles of mitochondria-generated reactive oxygen species on X-ray-induced apoptosis in a human hepatocellular carcinoma cell line, HLE. Free Radic Res 2012;46:1029-43.
52. Zhou J, Du Y. Acquisition of resistance of pancreatic cancer cells to 2-methoxyestradiol is associated with the upregulation of manganese superoxide dismutase. Mol Cancer Res 2012;10:768-77.
53. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 2010;12:662-7.